Assembly Biosciences Presents Data Highlighting Recurrent Genital Herpes Program at STI & HIV 2025 World Congress and International Herpesvirus Workshop

Core Insights - Assembly Biosciences, Inc. presented Phase 1a clinical and preclinical data for its herpes simplex virus helicase-primase inhibitor candidates ABI-5366 and ABI-1179 at major conferences in July 2025, indicating progress in their development [1][2][4] Group 1: Clinical Data and Presentations - Phase 1a clinical data for ABI-5366 and ABI-1179 were showcased in multiple poster presentations at the STI & HIV 2025 World Congress and the 49th Annual International Herpesvirus Workshop [1][4] - Interim proof-of-concept Phase 1b data for both candidates in participants with recurrent genital herpes is expected in fall 2025 [1] - The late-breaking poster for ABI-1179 included the first scientific presentation of its Phase 1a clinical data, showing no clinically significant food effect [2][4] Group 2: Treatment Potential and Dosing - Both candidates are designed to offer innovative treatment options, potentially allowing for once weekly or once monthly oral dosing, which would significantly reduce the treatment burden compared to current daily therapies [2] - The current standard of care for recurrent genital herpes has not seen new drug approvals in over 25 years, highlighting the need for new treatment options [10] Group 3: Preclinical Insights and Epidemiology - Additional posters reviewed preclinical studies of ABI-5366 and provided methodology for analyzing claims data on genital herpes prevalence and treatment patterns in the U.S. [3] - Epidemiological studies estimate that over four million people in the U.S. and several European countries experience recurrent genital herpes, with most individuals having multiple recurrences annually [10] Group 4: Mechanism of Action - HSV helicase-primase inhibitors target a viral enzyme complex essential for the herpes simplex virus, which has no equivalent in human hosts, suggesting a potentially superior efficacy compared to current nucleoside analog treatments [11] Group 5: Company Overview - Assembly Biosciences is focused on developing innovative small-molecule therapeutics aimed at serious viral diseases, with a commitment to improving patient outcomes [12]